Scarica l'app Stockscreener
2.16
10.77%
0.21
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLS Giù?
Forum
Previsione
Frazionamento azionario
Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie
SELLAS Life Sciences Holds Annual Stockholders Meeting - TipRanks
SELLAS Life Sciences: Tons Of Completed Studies (NASDAQ:SLS) - Seeking Alpha
Insider Buying: VAN NOSTRAND ROBERT L Acquires Additional Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus
SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Highs and Lows - investchronicle.com
Sellas Life Sciences director Van Nostrand buys $14,800 in stock By Investing.com - Investing.com South Africa
Sellas Life Sciences director Van Nostrand buys $14,800 in stock - Investing.com
SELLAS adds oncology experts to advisory board By Investing.com - Investing.com South Africa
SELLAS Life Sciences Expands Scientific Advisory Board with - GlobeNewswire
SELLAS Life Sciences Expands Scientific Advisory Board - citybiz
SELLAS adds oncology experts to advisory board - Investing.com
Leading Oncology Experts Join SELLAS Advisory Board as Critical AML Trial Results Near - Stock Titan
Northern Trust Corp Acquires 33,878 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
Insider Buying: Jane Wasman Acquires 20,000 Shares of SELLAS Lif - GuruFocus
SELLAS reports potential colorectal cancer therapy progress By Investing.com - Investing.com South Africa
SELLAS reports potential colorectal cancer therapy progress - Investing.com India
Insider Buying: Jane Wasman Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus
SELLAS Life Sciences (SLS) Highlights Promising Results for SLS0 - GuruFocus
Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual Meeting - marketscreener.com
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting - GlobeNewswire
Breakthrough at ASCO: SELLAS Drug Shows Powerful Response in Targeted Colorectal Cancer Treatment - Stock Titan
National Bank Financial Comments on CVE:SLS FY2026 Earnings - Defense World
Insider Buying: Katherine Kalin Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus
US futures and global markets tumble after Trump threatens European Union with 50% tariffs and Apple with 25% tariff - The Globe and Mail
Director Makes Bold Move with Major Stock Purchase in SELLAS Life Sciences Group - TipRanks
Sellas Life Sciences Reports Improved Financial Position - TipRanks
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase - The Manila Times
SELLAS Life Sciences CEO to Reveal Latest Cancer Drug Development Strategy at Major Healthcare Conference - Stock Titan
Sellas doses first paediatric subject with AML in Phase II trial of SLS009 - Yahoo Finance
SELLAS advances pediatric AML treatment with Phase 2 trial By Investing.com - Investing.com South Africa
Sellas Life Sciences Doses 1st Pediatric Patient in Acute Myeloid Leukemia Study - marketscreener.com
SELLAS Life Sciences (SLS) Advances Phase 2 Trial for Pediatric AML | SLS Stock News - GuruFocus
SELLAS advances pediatric AML treatment with Phase 2 trial - Investing.com
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - GlobeNewswire
Breakthrough: First Child with Resistant Leukemia Receives New Treatment in Major Clinical Trial - Stock Titan
SELLAS Life Sciences (SLS) Reports Improved Q1 Earnings Amid Fin - GuruFocus
SLS009 Shows Promising Results in Latest AML Trials | SLS Stock News - GuruFocus
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
SELLAS Life Sciences Group Reports Positive Overall Survival Data for SLS009 in r/r AML and Updates on Financial Position and Pipeline Developments - Nasdaq
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Upward Trajectory: SELLAS Life Sciences Group Inc (SLS) Posts a Gaine, Closing at 1.72 - DWinneX
Financial Metrics Exploration: Understanding SELLAS Life Sciences Group Inc (SLS) Through Ratios - DWinneX
Geode Capital Management LLC Purchases 128,355 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - Sete News
SELLAS Life Sciences Group Inc’s latest rating changes from various analysts - knoxdaily.com
SELLAS Life Sciences Group Inc (SLS) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Understanding the Risks of Investing in La Rosa Holdings Corp (LRHC) - knoxdaily.com
SELLAS reports promising AML treatment in preclinical study - Investing.com
0.39%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):